Novo Nordisk Invests BRL 6.4 Billion in Brazilian Manufacturing Expansion for Obesity Drugs
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion...
NYSE: NVO
Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China
In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...
Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA
China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug...
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...
Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies
US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...
Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities
Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference
Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...
Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study
Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...
United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...
Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease
Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement...
Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III...
Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative...
Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...
Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases
US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE:...
Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...
Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration...
CSPC Pharmaceutical’s SYH9017 Receives NMPA Clearance for Weight Management Clinical Trial
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National...
Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases
US-based Photys Therapeutics, Inc. has entered into an agreement with Denmark-based Novo Nordisk A/S (NYSE:...